Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com
Quote | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Last: | $2.29 |
---|---|
Change Percent: | -0.63% |
Open: | $2.38 |
Close: | $2.29 |
High: | $2.46 |
Low: | $2.24 |
Volume: | 566,839 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Cellectar Biosciences Inc. (NASDAQ:CLRB)
2024-07-24 15:22:07 ET Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call July 24, 2024, 08:00 AM ET Company Participants James Caruso - President and Chief Executive Officer Sikander Ailawadhi - Professor of Medicine at Mayo Clinic Michael Morris - Co-F...
2024-07-23 15:09:01 ET Summary Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's Macroglobulinemia or WM. The NDA submission of ipof...
Message Board Posts | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for First Quarter 2023 and Pro | whytestocks | investorshangout | 05/04/2023 12:55:45 PM |
whytestocks: $CLRB News Article - Cellectar Biosciences Reports Complete Response in a Relapsed/Refr | whytestocks | investorshangout | 02/28/2023 4:40:48 PM |
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Source:Edgar (US | abracky | investorshub | 12/12/2022 5:44:16 AM |
Look at $PSTV - All the due diligence | The Ultimate Choice | investorshub | 09/06/2022 1:47:38 PM |
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for Second Quarter 2022 | whytestocks | investorshangout | 08/05/2022 5:01:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...